RenewalBio

Based in Israel, RenewalBio specializes in advancing embryonic research through innovative synthetic models derived from naïve embryonic stem cells, enhancing the understanding of human development. RenewalBio, founded in 2022 and headquartered in Rehovot, Israel, develops innovative solutions for embryonic research. The company has executed one deal, with its most recent being on November 11, 2025. The company specializes in developing innovative solutions in the field of embryonic research, focusing on advanced models for understanding human development.

Their core products include synthetic embryonic models created from naïve embryonic stem cells, which facilitate groundbreaking research into early human development stages. Key publications from the company, such as "Ex utero mouse embryogenesis from pre-gastrulation to late organogenesis" and "Complete human day 14 post-implantation embryo models from naïve ES cells," highlight their advancements in this niche area of developmental biology. These products are primarily utilized by academic institutions, research laboratories, and biotechnology companies, particularly in North America, Europe, and parts of Asia, where there is a significant focus on regenerative medicine and developmental biology research. By providing these sophisticated models, the company aims to address challenges in understanding congenital diseases, reproductive health, and potential therapeutic applications.

The company's revenue is generated through collaborations and partnerships with research institutions and biotech firms, primarily through a B2B transaction structure. Clients typically engage the company to access its proprietary embryonic models and related services, which are integral for various research and development initiatives. Transactions are structured around project-based engagements or multi-year research agreements, where clients may commit to a series of studies utilizing the company's products. These agreements often involve upfront fees for access to the technology and subsequent payments tied to specific deliverables or outcomes.

The company’s revenue streams focus on their flagship products that are central to their research capabilities, ensuring that clients receive cutting-edge tools for their scientific inquiries. In December 2025, RenewalBio raised an undisclosed amount of venture funding from new investor YZi Labs. The company will use the funding to support the further development of its preclinical trials and the expansion of laboratory infrastructure. Future plans include designing and launching new products aimed at enhancing their existing synthetic embryonic models, targeting expeditions into new markets across Europe and Asia by early 2026.